Guardian Pharmacy Services, Inc. (GRDN) - 10-Q Summary
Business Context and Reporting Period
Company: Guardian Pharmacy Services, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A leading pharmacy services provider for long-term health care facilities (LTCFs), including assisted living and behavioral health facilities. As of September 30, 2025, the company operated 53 pharmacies serving approximately 204,000 residents across 38 states.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | 2025 (9 Months) | 2024 (9 Months) |
|---|---|---|
| Revenue | $1,051.1 million | $889.8 million |
| Gross Profit | $207.2 million | $177.3 million |
| Operating Income | $41.9 million | ($79.7 million) Loss |
| Net Income (GAAP) | $27.7 million | ($82.9 million) Loss |
| Net Income Attributable to Company | $28.3 million | ($122.0 million) Loss |
| Adjusted EBITDA | $75.7 million | $64.9 million |
| Cash & Equivalents (Sept 30, 2025) | $36.5 million | $4.7 million (Dec 31, 2024) |
| Operating Cash Flow | $65.7 million | $35.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 18.1% year-over-year, driven by $51.2 million from acquisitions and $110.0 million from organic growth (increased residents served and prescriptions dispensed).
- Profitability Turnaround: The company transitioned from a GAAP net loss of $82.9 million in the prior year to a net income of $27.7 million. This is primarily due to a significant reduction in share-based compensation expense.
- SG&A Reduction: Selling, general, and administrative expenses decreased 35.7% to $165.3 million. The prior year included a one-time $128.0 million share-based compensation charge related to the Corporate Reorganization and IPO. Excluding this, SG&A increased due to headcount growth.
- Interest Expense: Interest expense dropped 82.4% to $0.5 million as the company had no outstanding balances on its credit facility during the period.
- Acquisitions: Completed various pharmacy acquisitions in 2025 with total preliminary consideration of $16.3 million (cash, stock, and contingent payments).
Guidance, Outlook, and Risks
Outlook: Management expects to continue growing through a combination of organic expansion and acquisitions. The company serves a differentiated market (Assisted Living and Behavioral Health) which it views as the highest growth sector of the LTCF market.
Liquidity: The company holds $36.5 million in cash and has a $40 million line of credit available (with an option to increase to $75 million). Management believes existing resources are sufficient for the next 12 months.
Risks & Contingencies:
- Regulatory & Reimbursement: Risks related to government efforts to lower pharmaceutical costs and changes in reimbursement rates from health plan payors.
- Legal Proceedings: Subject to ordinary course litigation; no material adverse effects currently anticipated.
- Supply Chain: Exposure to manufacturing disruptions and trade policies affecting pharmaceutical availability.
- Forward-Looking Statements: Actual results may differ due to factors including competition, ability to retain management, and cybersecurity threats.
Investor Verification Checklist
- Share-Based Compensation Normalization: Verify the sustainability of profitability by analyzing Adjusted EBITDA and Adjusted Net Income, as GAAP results were heavily skewed by a one-time $128M expense in 2024.
- Acquisition Integration: Monitor the performance of 2025 acquisitions and the realization of projected synergies.
- Reimbursement Rates: Track changes in reimbursement rates from health plan payors and the impact on gross margins.
- Debt Covenants: Review the terms of the Credit Facility (maturity April 2027) and ensure compliance with financial ratios.
- Class B Conversion: Note the automatic conversion schedule of Class B common stock to Class A, which impacts share count and dilution.